All articles tagged: Chronic lymphocytic leukemia of B-cell type in remission (C91.11)


Evalytics 19 March at 06.04 AM FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
HealthDay 13 December at 03.59 PM ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held f # Pharmacy # Hematology & Oncology 0 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn

Evalytics 19 March at 06.04 AM

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif

1 Likes

0 Comments

HealthDay 13 December at 03.59 PM

ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia

For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held f

# Pharmacy # Hematology & Oncology

0 Likes

0 Comments


Medpage Today 17 November at 10.31 PM Two Treatments That Don't Work for Osteoarthritis WASHINGTON -- If you're looking for nonsurgical osteoarthritis (OA) treatments with fewer side effects than ordinary pain relievers, two randomized trials presented here with negative results should at least narrow your search... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
MedScape 11 November at 07.56 AM Scoring System Could Mean Better Access to Lung Transplant Scoring system could improve access for hard-to-match candidates due to height and blood type. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 07 November at 07.50 AM How key results could influence health policy The results of some congressional races may foreshadow who will have outsize health policy influence in Congress next year. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medpage Today 05 November at 07.00 PM Mpox Cases in Congo May Be Stabilizing GOMA, Congo -- Some health officials say mpox cases in Congo appear to be "stabilizing" -- a possible sign that the main epidemic for which the World Health Organization (WHO) made a global emergency declaration in August... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 02 November at 07.40 AM Insulin resistance caused by sympathetic nervous system over-activation, a paradigm-shifting study finds Rutgers Robert Wood Johnson Medical School and collaborating institutions have found that overnutrition leads to insulin resistance and metabolic disorders through increased activity of the sympathetic nervous system (SNS). The study shows that reducing SNS activity can prevent insulin resistance induced by a high-fat diet, suggesting a new understanding of how obesity causes insulin resistance. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
MedScape 31 October at 06.30 AM Report: Rethink Race-Based Adjustments in Clinical Tools The slow adoption of race-neutral tools may harm patient care outcomes, according to a new report from the National Academies of Sciences, Engineering, and Medicine. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn

Medpage Today 25 October at 02.09 PM Patients More Satisfied With AI's Answers Than Those From Their Doctor Patients were consistently more satisfied with responses from artificial intelligence (AI) to messages in the electronic health record than they were with those from their clinician, according to a study in JAMA Network Open... 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 25 October at 12.40 PM Surgical innovation: The intelligent turbine insufflator The Politecnico di Milano and the Erasmus Medical Center in Rotterdam have pooled their medical and technical expertise to create a new technology for devices called "insufflators." These innovative instruments are designed to create a temporary cavity in the bodies of patients through the application of pressurized gas, providing the surgeon with the necessary space to perform the surgical proced 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
Medical xPress 24 October at 07.50 AM Genetic variants in melatonin receptor linked to idiopathic osteoporosis Columbia University Medical Center researchers have identified specific variants in a melatonin receptor gene that impair bone turnover, leading to significant reductions in bone density and increased risk of fractures, particularly in Ashkenazi Jewish individuals. 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn
HealthDay 23 October at 10.58 PM Risk for Psychiatric Disorders Up for Offspring of Moms With Eating Disorder Offspring of mothers with an eating disorder or prepregnancy body mass index (BMI) outside the normal weight range have an increased risk for psychiatric disorders, according to a study published online Oct. 22 in JAMA Network Open.Ida A.K. Nilsson, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a popula 1 Likes 0 Comments 0 Shares Facebook Twitter LinkedIn